Citadel Advisors
ACUR

Citadel Advisors’s Acura Pharmaceuticals ACUR Stock Holding History

Citadel Advisors’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-360
Closed -$3K – 8165
2013
Q4 		$3K Sell
360
-2,140
-86% -$18.1K ﹤0.01% 6885
2013
Q3 		$24K Buy
2,500
+60
+2% +$531 ﹤0.01% 6135
2013
Q2 		$23K Buy
+2,440
New +$27.6K ﹤0.01% 6019

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Citadel Advisors's ACUR Position: Q4 2016 in Review

Citadel Advisors sold out of Acura Pharmaceuticals (ACUR) in Q4 2016, closing a stake of 30,483 shares — an estimated $49K sold.

Citadel Advisors first reported a position in ACUR in Q4 2013 and held it in 5 quarters. The position peaked at $49K in Q3 2016. 22 funds tracked by Wall St. Rank hold ACUR as of Q4 2016.

  • Citadel Advisors reported no remaining Acura Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Citadel Advisors sold 30,483 Acura Pharmaceuticals shares in Q4 2016, an estimated $49K.
  • Citadel Advisors first reported a position in Acura Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Citadel Advisors's Acura Pharmaceuticals position peaked at $49K in Q3 2016.
  • 22 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q4 2016.

Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.